Terapia-alvo contra KRAS dá novo fôlego ao tratamento do câncer de pâncreas
An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented today at the ESMO Gastrointestinal Cancers Cong
